03 Ingredient sourcing
Urolithin A
3,8-dihydroxybenzo[c]chromen-6-one
Urolithin A is one of the most talked-about longevity ingredients, with premium retail prices to match. Quality between producers varies widely. We find manufacturers that can prove purity, check every document in Chinese, and help you source at a sensible price.
- Form covered
- Synthesised urolithin A, high-purity powder
Why brands source it
Urolithin A is described in its US GRAS notice as 3,8-dihydroxybenzo[c]chromen-6-one, a beige to yellow powder, identical in structure to the compound formed in the gut from dietary ellagitannins [1].
FDA responded to that notice, GRN 791 from Amazentis SA, with a “no questions” letter in December 2018 [1]. A novel food application for urolithin A has also been submitted in the EU [3]. Neither instrument automatically covers another supplier’s material or your intended use.
For a brand, the attraction of a defined compound is that it can be specified tightly. The risk is that a small number of producers, and a patent landscape that needs checking, limit the real choice of supplier.
Where it is used
Softgels and capsules
The most common format for daily urolithin A products.
Powders and sachets
Flavoured powders mixed into drinks or smoothies.
Gummies
Chewable formats aimed at a broader audience.
Longevity and active-ageing ranges
Positioned in premium healthy-ageing, muscle and mitochondrial-health product lines.
Well-known products that contain it
- Timeline Mitopure softgels, gummies and powder
- Pure Encapsulations (Nestlé Health Science) Products using Mitopure
Listed as market examples. Brand names belong to their owners.
What usually goes wrong
- 01
Purity without the route
A 98% or 99% purity claim says nothing about what the remaining fraction is. The synthesis route determines which impurities, solvents and catalyst residues to look for. Without the route, the impurity profile cannot be read.
- 02
Isomers and related urolithins not separated
Positional isomers and related urolithins can sit close to urolithin A on a chromatogram. The HPLC method needs to be specific for urolithin A, and the supplier should show how that specificity was demonstrated.
- 03
Catalyst metals ignored
Where metal catalysts are used in synthesis, residual metals should be assessed in addition to the usual heavy metals, using a framework such as ICH Q3D [5].
- 04
Solvents reported as “conforms”
Residual solvents should be named and quantified against ICH Q3C classes [4], matching the solvents on the process flow chart.
- 05
A sample that does not represent production
Small producers sometimes supply a lab-scale sample. Ask how many commercial-scale lots have been made and request COAs from them.
What we check
Typical specification areas and the test methods we expect to see. Numeric targets are set per brief, against your specification and your markets.
| Specification area | Test method | What we look for |
|---|---|---|
| Assay and purity | HPLC with chromatogram, method summary, reference standard | Purity minimum set to your specification. Specificity against related isomers. |
| Identity | HPLC retention plus a second technique such as NMR, MS or IR | Structure confirmed, not only retention time. |
| Related substances and isomers | HPLC impurity profile with named impurities | Each impurity above the reporting threshold named and quantified. |
| Synthesis route | Route summary, starting materials, reagents and catalysts | Shared under NDA if needed. Drives every impurity test below. |
| Residual solvents | Headspace GC against ICH Q3C [4] | Matches the solvents named in the route. |
| Catalyst and elemental impurities | ICP-MS, assessed against ICH Q3D [5] and USP 2232 [7] | Includes metals used as catalysts, not only Pb, Cd, As and Hg. |
| Stability | Real-time and accelerated stability data [6] | Supports the retest or expiry date. |
| Laboratory | ISO/IEC 17025 accreditation, scope checked per test [10] | Independent confirmation of purity on a production lot. |
Documents we request
- Lot-specific COA with HPLC chromatogram and impurity profile
- Specification sheet naming the method for every parameter
- Synthesis route summary, starting materials, solvents and catalysts (under NDA if required)
- Residual solvent and elemental impurity statement
- Stability study summary
- COAs from at least three commercial-scale lots
- Regulatory documents the supplier relies on, for your counsel to review
- Statement on patents or licences covering the product, process or intended uses, for your counsel to review
Red flags
- Purity stated with no chromatogram or impurity profile
- Supplier will not describe the route, even under NDA
- No residual solvent or catalyst metal data
- Only lab-scale samples, no commercial lot history
- Supplier presents another company’s GRAS notice as covering its own material
- Price far below the established producers with no explanation of the route
Sourcing notes
Urolithin A sourcing is decided as much by regulatory and patent questions as by chemistry. Put them in order.
- Regulatory status first. A GRAS “no questions” letter answers a specific notifier’s conclusion about its own material and intended uses [1]. Whether your product needs its own notification, for example a new dietary ingredient notification in the US [8], or an authorisation in other markets [3], is for qualified regulatory counsel.
- Patents second. Ask each supplier in writing what patents or licences cover its process and product, and have your counsel review the answer. Public databases such as Espacenet are a starting point [9].
- Supplier depth third. Treat supply concentration as a risk to verify. Ask how many commercial lots each candidate has made, for whom it can provide references, and whether it will commit to notify you of route or site changes.
Once those are settled, the technical file decides between the remaining candidates. That is where we spend most of our time.
Sources
- [1] US Food and Drug Administration. GRAS Notice No. 791, Urolithin A, notifier Amazentis SA. Closed 20 December 2018, FDA has no questions. www.hfpappexternal.fda.gov/scripts/fdcc/index.cfm?set=grasnotices&id=791
- [2] Amazentis SA. GRAS notice for urolithin A (releasable information), submitted to FDA. www.fda.gov/media/132889/download
- [3] European Commission. Summary of application for the approval of urolithin A as a novel food (application 2018-0538). food.ec.europa.eu/food-safety/novel-food/authorisations/summary-applications-and-notifications_en
- [4] International Council for Harmonisation. ICH Q3C, Impurities. Guideline for residual solvents. www.ich.org/page/quality-guidelines
- [5] International Council for Harmonisation. ICH Q3D, Guideline for elemental impurities. www.ich.org/page/quality-guidelines
- [6] International Council for Harmonisation. ICH Q1A(R2), Stability testing of new drug substances and products. www.ich.org/page/quality-guidelines
- [7] United States Pharmacopeia. General Chapter 2232, Elemental contaminants in dietary supplements.
- [8] US Food and Drug Administration. New Dietary Ingredient (NDI) Notification Process. www.fda.gov/food/dietary-supplements/new-dietary-ingredient-ndi-notification-process
- [9] European Patent Office. Espacenet patent search. worldwide.espacenet.com/
- [10] ISO/IEC 17025:2017, General requirements for the competence of testing and calibration laboratories. International Organization for Standardization. www.iso.org/standard/66912.html
Next step
Need a reliable Urolithin A supplier?
Tell us your target quality and volumes. We reply within two working days with a sourcing plan and a fixed quote.